Malignant Neoplasm of Breast
Conditions
Keywords
metastatic breast cancer (MBC)
Brief summary
The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
Interventions
DRUGpalbociclib
patients on palbociclib combination treatment
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33) 2. Age ≥18 years at index date
Exclusion criteria
There are no
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients on treatment | 01 January 2017 until 30 September 2020 | Proportion of patients who have not discontinued treatment will be assessed at various timepoints (Time Frame: treatment start date through end of study \[assessed up to 48 months\]) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients alive | 01 January 2017 until 30 September 2020 | Proportion of patients alive on palbociclib combination treatment at different points in time (Time Frame: treatment start date through end of study \[assessed up to 48 months\]) |
| Describe the demographic and clinical characteristics of the patient population receiving palbociclib combination treatment | 01 January 2017 until 30 September 2020 | — |
Countries
Sweden
Contacts
CONTACTPfizer CT.gov Call Center
STUDY_DIRECTORPfizer CT.gov Call Center
Pfizer
Outcome results
None listed